RYDAPT is a Oral Capsule, Liquid Filled in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Midostaurin.
Product ID | 0078-0698_259ff0ac-725c-4f95-8616-e2285b6a5bc9 |
NDC | 0078-0698 |
Product Type | Human Prescription Drug |
Proprietary Name | RYDAPT |
Generic Name | Rydapt |
Dosage Form | Capsule, Liquid Filled |
Route of Administration | ORAL |
Marketing Start Date | 2017-04-28 |
Marketing Category | NDA / NDA |
Application Number | NDA207997 |
Labeler Name | Novartis Pharmaceuticals Corporation |
Substance Name | MIDOSTAURIN |
Active Ingredient Strength | 25 mg/1 |
Pharm Classes | Kinase Inhibitor [EPC],Receptor Tyrosine Kinase Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2019-12-31 |
Marketing Start Date | 2017-04-28 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA207997 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2017-04-28 |
Marketing Category | NDA |
Application Number | NDA207997 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2017-04-28 |
Marketing Category | NDA |
Application Number | NDA207997 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2017-04-28 |
Marketing Category | NDA |
Application Number | NDA207997 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2017-04-28 |
Ingredient | Strength |
---|---|
MIDOSTAURIN | 25 mg/1 |
SPL SET ID: | 11fa3fc9-6776-49a6-b1c1-653f627c3e58 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
RYDAPT 79149774 4710118 Live/Registered |
Novartis AG 2014-06-04 |
RYDAPT 79043585 3441082 Dead/Cancelled |
Novartis AG 2007-08-31 |